Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents

Journal of Hypertension

Volumn 22, Issue 7, 2004, Pages 1409-1414

  Girvin, Briegeen G ^a   Johnston, G Dennis ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antihypertensive withdrawal; Dose omission; Electronic monitoring; Hypertension; Medication Event Monitoring System; Patient compliance

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; ENALAPRIL; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MONITOR; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 3042759494     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000125440.28861.d6     Document Type: Article

References (21)

1. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986; 29 (Suppl 1):99-118.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH; Eberlein KA, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 333:827-838.
3. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32:345-356.
4. Biston P, Melot C, Degaute JP, Clement D, Quoidbach A. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Press 1999; 8:43-48.
5. Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparision of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens 2002; 20:333-338.
6. Hwang Y, Yen H. Amlodipine - once daily monotherapy in systemic hypertension. Am J Cardiol 1994; 73:1230-1232.
7. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41:83-88.
8. de la Figuera M, Rodriguez JAS. Duration of trandolapril antihypertensive effect after 24 and 48 hours from last dose: THOR study. Clin Drug Invest 1999; 17:43-50.
9. Mallion JM, Dutrey-Dupagne C, Vaur L, Genes N, Renault M, Elkik F, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996; 14:137-144.
10. Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, Bouviere d'Yvoire M, Elkik F, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995; 26:127-131.
11. Lacourciere Y, Asmar R, for the Candesartan/Losartan Study Investigators. A comparison of the efficacy and duration of action of candesartan cilexitil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999; 12:1181-1187.
12. Lasko BH, Laplante A, Herbert D, Bonnefis-Boyer S. Canadian valsartan study in patients with mild to moderate hypertension. Blood Press Monit 2001; 6:91-99.
13. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. www.wma.net/e/policy/17-c_e.html [2000]
14. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance. Good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 1990; 67:361-372.
15. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536.
16. Hernandez RH, Armas-Hernandez MJ, Chourio JA, Armas-Padilla MC, Lopez L, Alvarez M, et al. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit 2001; 6:47-57.
17. Meredith P, Elliott H. Therapeutic coverage: reducing the risks of partial compliance. Br J Clin Pract Symp Suppl 1994; 73:13-17.
18. Haynes RB. Strategies for improving compliance: a methodologic analysis and review. In: Sackett DL, Haynes RB (editors): Compliance with therapeutic regimens. Baltimore: John Hopkins University Press; 1976, pp. 69-82.
19. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men - a meta-analysis of individual patient data from randomized controlled trials. Ann Intern Med 1997; 126:761-769.
20. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
21. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13:569-592.